全文获取类型
收费全文 | 9865篇 |
免费 | 1146篇 |
国内免费 | 182篇 |
专业分类
耳鼻咽喉 | 68篇 |
儿科学 | 190篇 |
妇产科学 | 58篇 |
基础医学 | 1160篇 |
口腔科学 | 1168篇 |
临床医学 | 727篇 |
内科学 | 1274篇 |
皮肤病学 | 99篇 |
神经病学 | 1633篇 |
特种医学 | 307篇 |
外科学 | 939篇 |
综合类 | 1006篇 |
预防医学 | 814篇 |
眼科学 | 759篇 |
药学 | 566篇 |
14篇 | |
中国医学 | 184篇 |
肿瘤学 | 227篇 |
出版年
2024年 | 20篇 |
2023年 | 135篇 |
2022年 | 423篇 |
2021年 | 495篇 |
2020年 | 400篇 |
2019年 | 406篇 |
2018年 | 392篇 |
2017年 | 426篇 |
2016年 | 451篇 |
2015年 | 464篇 |
2014年 | 626篇 |
2013年 | 730篇 |
2012年 | 551篇 |
2011年 | 633篇 |
2010年 | 505篇 |
2009年 | 444篇 |
2008年 | 414篇 |
2007年 | 393篇 |
2006年 | 322篇 |
2005年 | 321篇 |
2004年 | 253篇 |
2003年 | 257篇 |
2002年 | 235篇 |
2001年 | 193篇 |
2000年 | 133篇 |
1999年 | 124篇 |
1998年 | 133篇 |
1997年 | 115篇 |
1996年 | 125篇 |
1995年 | 90篇 |
1994年 | 89篇 |
1993年 | 70篇 |
1992年 | 85篇 |
1991年 | 86篇 |
1990年 | 60篇 |
1989年 | 57篇 |
1988年 | 55篇 |
1987年 | 60篇 |
1986年 | 66篇 |
1985年 | 66篇 |
1984年 | 48篇 |
1983年 | 42篇 |
1982年 | 42篇 |
1981年 | 53篇 |
1980年 | 32篇 |
1979年 | 18篇 |
1978年 | 19篇 |
1977年 | 5篇 |
1976年 | 9篇 |
1973年 | 8篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
1.
目的探讨脑卒中患者急性应激障碍发生现状及影响因素。方法采用斯坦福急性应激反应问卷对349例脑卒中住院患者进行调查。结果共163例(46.70%)患者发生急性应激障碍;Logistic回归分析结果显示,患者性格、是否存在偏瘫及是否吞咽功能障碍是脑卒中患者发生急性应激障碍的主要影响因素(P0.05,P0.01)。结论脑卒中患者急性应激障碍发生率较高,内向性格及存在偏瘫和吞咽功能障碍的患者更容易发生急性应激障碍。医护人员应及时为高危患者提供个体化治疗及预见性护理,防止脑卒中患者发生急性应激障碍。 相似文献
2.
3.
《Vaccine》2022,40(11):1594-1605
In addition to providing pathogen-specific immunity, vaccines can also confer nonspecific effects (NSEs) on mortality and morbidity unrelated to the targeted disease. Immunisation with live vaccines, such as the BCG vaccine, has generally been associated with significantly reduced all-cause infant mortality. In contrast, some inactivated vaccines, such as the diphtheria, tetanus, whole-cell pertussis (DTPw) vaccine, have been controversially associated with increased all-cause mortality especially in female infants in high-mortality settings. The NSEs associated with BCG have been attributed, in part, to the induction of trained immunity, an epigenetic and metabolic reprograming of innate immune cells, increasing their responsiveness to subsequent microbial encounters. Whether non-live vaccines such as DTPw induce trained immunity is currently poorly understood. Here, we report that immunisation of mice with DTPw induced a unique program of trained immunity in comparison to BCG immunised mice. Altered monocyte and DC cytokine responses were evident in DTPw immunised mice even months after vaccination. Furthermore, splenic cDCs from DTPw immunised mice had altered chromatin accessibility at loci involved in immunity and metabolism, suggesting that these changes were epigenetically mediated. Interestingly, changing the order in which the BCG and DTPw vaccines were co-administered to mice altered subsequent trained immune responses. Given these differences in trained immunity, we also assessed whether administration of these vaccines altered susceptibility to sepsis in two different mouse models. Immunisation with either BCG or a DTPw-containing vaccine prior to the induction of sepsis did not significantly alter survival. Further studies are now needed to more fully investigate the potential consequences of DTPw induced trained immunity in different contexts and to assess whether other non-live vaccines also induce similar changes. 相似文献
4.
5.
《Diagnostic Histopathology》2019,25(9):360-366
Sudden death in childhood and adolescence is fortunately rare. However, when it occurs, it can have a devastating effect on the family. Therefore, these cases should be thoroughly investigated, including a complete post mortem examination by a specialist in paediatric pathology. The aim is to identify the cause of death, and potentially prevent future deaths. This review will provide an overview of the epidemiology of sudden death in childhood and adolescence and will outline the wide range of causes of death identified. Certain aspects of the paediatric post mortem examination will be discussed, and will finish with a section on deaths in children with chronic medical conditions. 相似文献
6.
Luis Veloza Cristina Teixido Natalia Castrejon Fina Climent Ana Carri Marta Marginet Davide Soldini Blanca Gonzlez‐Farr Inmaculada Ribera‐Cortada Armando Lopez‐Guillermo Eva Gonzlez‐Barca Adriana Sierra Mileyka Herrera Cndida Gmez Adriana Garcia Olga Balagu Elias Campo Antonio Martinez 《Histopathology》2019,75(6):799-812
7.
8.
9.
10.
Altan Ahmed John A. Stauffer Jordan D. LeGout Justin Burns Kristopher Croome Ricardo Paz-Fumagalli Gregory Frey Beau Toskich 《Journal of gastrointestinal oncology.》2021,12(2):751
BackgroundNeoadjuvant yttrium-90 transarterial radioembolization (TARE) is increasingly being used as a strategy to facilitate resection of otherwise unresectable tumors due to its ability to generate both tumor response and remnant liver hypertrophy. Perioperative outcomes after the use of neoadjuvant lobar TARE remain underinvestigated.MethodsA single center retrospective review of patients who underwent lobar TARE prior to major hepatectomy for primary or metastatic liver cancer between 2007 and 2018 was conducted. Baseline demographics, radioembolization parameters, pre- and post-radioembolization volumetrics, intra-operative surgical data, adverse events, and post-operative outcomes were analyzed.ResultsTwenty-six patients underwent major hepatectomy after neoadjuvant lobar TARE. The mean age was 58.3 years (17–88 years). 62% of patients (n=16) had primary liver malignancies while the remainder had metastatic disease. Liver resection included right hepatectomy or trisegmentectomy, left or extended left hepatectomy, and sectorectomy/segmentectomy in 77% (n=20), 8% (n=2), and 15% (n=4) of patients, respectively. The mean length of stay was 8.3 days (range, 3–33 days) and there were no grade IV morbidities or 90-day mortalities. The incidence of post hepatectomy liver failure (PHLF) was 3.8% (n=1). The median time to progression after resection was 4.5 months (range, 3.3–10 months). Twenty-three percent (n=6) of patients had no recurrence. The median survival was 28.9 months (range, 16.9–46.8 months) from major hepatectomy and 37.6 months (range, 25.2–53.1 months) from TARE.ConclusionsMajor hepatectomy after neoadjuvant lobar radioembolization is safe with a low incidence of PHLF. 相似文献